Advertisement

Clinical & Experimental Metastasis

, Volume 25, Issue 6, pp 643–655 | Cite as

Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression

  • Laurie G. Hudson
  • Reema Zeineldin
  • M. Sharon Stack
Research Paper

Abstract

The mesodermally derived normal ovarian surface epithelium (OSE) displays both epithelial and mesenchymal characteristics and exhibits remarkable phenotypic plasticity during post-ovulatory repair. The majority of epithelial ovarian carcinomas (EOC) are derived from the OSE and represent the most lethal of all gynecological malignancies, as most patients (∼70%) present at diagnosis with disseminated intra-abdominal metastasis. The predominant pattern of EOC metastasis involves pelvic dissemination rather than lymphatic or hematologic spread, distinguishing EOC from other solid tumors. Acquisition of the metastatic phenotype involves a complex series of interrelated cellular events leading to dissociation (shedding) and dispersal of malignant cells. A key event in this process is disruption of cell–cell contacts via modulation of intercellular junctional components. In contrast to most carcinomas that downregulate E-cadherin expression during tumor progression, a unique feature of primary well-differentiated ovarian cancers is a gain of epithelial features, characterized by an increase in expression of E-cadherin. Subsequent reacquisition of mesenchymal features is observed in more advanced tumors with concomitant loss of E-cadherin expression and/or function during progression to metastasis. The functional consequences of this remarkable phenotypic plasticity are not fully understood, but may play a role in modulation of cell survival in suspension (ascites), chemoresistance, and intraperitoneal anchoring of metastatic lesions.

Keywords

Ovarian cancer Epithelium Cadherin Keratin Vimentin Epithelial–mesenchymal transition Plasticity 

Notes

Acknowledgments

This work was supported by National Cancer Institute Research Grants RO1CA090492 (LGH), CA109545 (MSS), and CA86984 (MSS). The authors wish to gratefully acknowledge the Robert H. Lurie Comprehensive Cancer Center Pathology Core Facility for ovarian tumor tissues and Dr. Brian P. Adley (Lutheran General Hospital, IL) for scoring of the immunohistochemical analyses.

References

  1. 1.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics. Clin 57(1):43–66 2007 Jan-FebGoogle Scholar
  2. 2.
    Wheeler JE (1993) Pathology of malignant ovarian epithelial tumors and miscellaneous and rare ovarian and paraovarian neoplasms. In: Rubin SC, Sutton GP (eds) Ovarian Cance, McGraw Hill, pp 87–130Google Scholar
  3. 3.
    Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351:2519–2529PubMedGoogle Scholar
  4. 4.
    DuBeau L (1999) The cell or origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gyn Oncol 72:437–442Google Scholar
  5. 5.
    Shedden KA, Kshisagar MP, Schwartz DR, Wu R, Yu H, Misek DE, Hanash S, Katabuchi H, Ellenson LH, Fearon ER, Cho KC (2005) Histologic type, organ or origin and wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clin Can Res 11:2123–2131Google Scholar
  6. 6.
    Shih IM, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Path 164:1511–1518PubMedGoogle Scholar
  7. 7.
    Schwartz DR, Kardia SLR, Shedden KA, Kuick R, Michailidis G, Taylor JMG, Misek DE, Wu R, Zhai Y, Darrah DM, Reed H, Ellenson LH, Giordano TJ, Rearon ER, Hanash SM, Cho KR (2002) Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Can Res 62:4722–4729Google Scholar
  8. 8.
    Scully RE, Young RH, Clement PB (1998) Tumors of the ovary, maldeveloped gonads, fallopian tube and broad ligament. Atlas of tumor pathology, third series, Fascicle 23Google Scholar
  9. 9.
    Ghosh S, Wu Y, Stack MS (2002) Ovarian cancer proteinases. Cancer Treat Res 107:331–351PubMedGoogle Scholar
  10. 10.
    Skubitz APN (2002) Adhesion molecules. Cancer Treat Res 107:305–329PubMedGoogle Scholar
  11. 11.
    Hoskins WJ (1995) Prospective on ovarian cancer: why prevent? J Cell Biochem suppl 23:189–199PubMedGoogle Scholar
  12. 12.
    Naora H, Montell DJ (2005) Ovarian cancer metastasis: integrating insights from disparate model organisms. Nature Rev Cancer 5:355–366Google Scholar
  13. 13.
    Wong AST, Auersperg N (2002) Normal Ovarian Surface Epithelium. Cancer Treat Res 107:161–183PubMedGoogle Scholar
  14. 14.
    Czernobilsky B, Moll R, Levy M, Franke WW (1985) Co-expression of cytokeratin and vimentin filaments in mesothelial, granulosa and rete ovarii cells of the human ovary. Eur J of Cell Biology 37:175–190Google Scholar
  15. 15.
    Auersperg N, Ota T, Mitchell GW (2002) Early events in ovarian epithelial carcinogenesis: progress and problems in experimental approaches. Int J Gynecol Cancer 12(6):691–703PubMedGoogle Scholar
  16. 16.
    Sundfeldt K, Piontkewitz Y, Ivarsson K, Nilsson O, Hellberg P, Brannstrom M, Janson PO, Enerback S, Hedin L (1997) E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int J Can 74:275–280Google Scholar
  17. 17.
    Okamura H, Katabuchi H, Nitta M, Ohtake H (2006) Structural changes and cell properties of human ovarian surface epithelium in ovarian pathophysiology. Microsc Res Tech 69:469–481PubMedGoogle Scholar
  18. 18.
    Peralta-Soler A, Knudsen KA, Tecson-Miguel A, McBrearty FX, Han AC, Salazar H (1997) Expression of E-cadherin and N-cadherin in surface epithelial stromal tumors of the ovary distinguishes mucinous from serous and endometrioid tumors. Human Path 28:734–739Google Scholar
  19. 19.
    Wong AST, Maines-Bandiera SL, Rosen B, Wheelock MJ, Johnson KR, Leung PCK, Roskelley CD, Auersperg N (1999) Constitutive and conditional cadherin expression in cultured human ovarian surface epithelium: influence of family history of ovarian cancer. Int J Can 81:180–188Google Scholar
  20. 20.
    Patel IS, Madan P, Getsios S, Bertrand MA, MacCalman CD (2003) Cadherin switching in ovarian cancer progression. Int J Can 106:172–177Google Scholar
  21. 21.
    Darai E, Scoazec JY, Walker-Combrouze F, Mlika-Cabanne N, Feldmann G, Madelenat P, Potet F (1997) Expression of cadherins in benign, borderline and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Path 28:922–928PubMedGoogle Scholar
  22. 22.
    Alper O, De Santis ML, Stromberg K, Hacker NF, Cho-Chung YS, Salomon DS (2000) Anti-sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell-adhesion and tumorigenicity in ovarian cancer cells. Int J Cancer 88(4):566–574PubMedGoogle Scholar
  23. 23.
    Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K, Stetler-Stevenson WG (2001) Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 93:1375–1384PubMedGoogle Scholar
  24. 24.
    Auersperg N, Maines-Bandiera Sl, Dyck HG, Kruk PA (1994) Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes. Lab Invest 71:510–518PubMedGoogle Scholar
  25. 25.
    Naora H (2007) The heterogeneity of epithelial ovarian cancers: reconciling old and new paradigms. Expert Rev Mol Med 9:1–12PubMedCrossRefGoogle Scholar
  26. 26.
    Hay ED (2005) EMT concept and examples from the vertebrate embryo In: Savagner P (ed) Rise and fall of epithelial phenotype: concepts of epithelial–mesenchymal transition. Springer, Berlin, pp 111–134Google Scholar
  27. 27.
    Peinado H, Portillo F, Cano A (2004) Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol 48:365–375PubMedGoogle Scholar
  28. 28.
    Huber MA, Kraut N, Beug H (2005) Molecular requirements for epithelial–mesenchymal transition during tumor progression. Curr Opin Cell Biol 17:548–558PubMedGoogle Scholar
  29. 29.
    Van Marck VL, Bracke ME (2005) Epithelial–mesenchymal transitions in human cancer. In: Savagner P (ed) Rise and fall of epithelial phenotype: concepts of epithelial–mesenchymal transition. Springer, Berlin, pp 111–134Google Scholar
  30. 30.
    Guarino M, Rubino B, Ballabio G (2007) The role of epithelial–mesenchymal transition in cancer pathology. Pathology 39:305–318PubMedGoogle Scholar
  31. 31.
    Tse JC, Kalluri R (2007) Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 101(4):816–829PubMedGoogle Scholar
  32. 32.
    Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T (2005) Opinion: migrating cancer stem cells—an integrated concept of malignant tumour progression. Nat Rev Cancer 5:744–749PubMedGoogle Scholar
  33. 33.
    Christiansen JJ, Rajasekaran AK (2006) Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 66:8319–8326PubMedGoogle Scholar
  34. 34.
    Ahmed N, Maines-Bandiera S, Quinn MA, Unger WG, Dedhar S, Auersperg N (2006) Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. Am J Physiol Cell Physiol 290(6):C1532–C1542PubMedGoogle Scholar
  35. 35.
    Come C, Magnino F, Bibeau F, De Santa Barbara P, Becker KF, Theillet C, Savagner P (2006) Snail and slug play distinct roles during breast carcinoma. Clin Cancer Res 12:5395–5402PubMedGoogle Scholar
  36. 36.
    Arnoux V, Come C, Kusewitt D, Hudson L, Savagner P (2005) Cutaneous Wound Reepithelializaton: A partial and reversible EMT. In: Savagner P (ed) Rise and fall of epithelial phenotype: concepts of epithelial–mesenchymal transition. Springer, Berlin, pp 111–134Google Scholar
  37. 37.
    Moreno-Bueno G, Cubillo E, Sarrio D, Peinado H, Rodriguez-Pinilla SM, Villa S, Bolos V, Jorda M, Fabra A, Portillo F, Palacios J, Cano A (2006) Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for snail, slug, and e47 factors in epithelial–mesenchymal transition. Cancer Res 66:9543–9556PubMedGoogle Scholar
  38. 38.
    Fodde R, Brabletz T (2007) Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 19:150–158PubMedGoogle Scholar
  39. 39.
    Chaffer CL, Thompson EW, Williams ED (2007) Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs 185:7–19PubMedGoogle Scholar
  40. 40.
    McLachlan RW, Yap AS (2007) Not so simple: the complexity of phosphotyrosine signaling at cadherin adhesive contacts. J Mol Med 85:545–554PubMedGoogle Scholar
  41. 41.
    Derycke LDM, Bracke ME (2004) N-cadherin in the spotlight of cell–cell adhesion, differentiation, embryogenesis, invasion and signaling. Int J Dev Biol 48:463–476PubMedGoogle Scholar
  42. 42.
    Conacci-Sorrell M, Zhurnisnsky J, Ben-Ze’ev A (2002) The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest 109:987–991PubMedGoogle Scholar
  43. 43.
    Arthur WT, Noren NK, Burridge K (2002) Regulation of Rho family GTPases by cell–cell and cell–matrix adhesion. Biol Res 35:239–246PubMedCrossRefGoogle Scholar
  44. 44.
    Pece S, Chiariello M, Murga C, Gutkind JS (1999) Activation of the protein kinase Akt/PKB by the formation of E-cadherin-mediated cell–cell junctions. J Biol Chem 274:19347–19351PubMedGoogle Scholar
  45. 45.
    Munshi HG, Ghosh S, Mukhopadhyay S, Wu YI, Sen R, Green KJ, Stack MS (2002) Proteinase suppression by E-cadherin-mediated cell–cell attachment in premalignant oral keratinocytes. J Biol Chem 277:38159–38167PubMedGoogle Scholar
  46. 46.
    Pece S, Gutkind JS (2000) Signaling from E-cadherins to the MAPK pathway by the recruitment and activation of epidermal growth factor receptors upon cell–cell contact formation. J Biol Chem 275:41227–41233PubMedGoogle Scholar
  47. 47.
    Wheelock MJ, Johnson KR (2003) Cadherin-mediated cellular signaling. Curr Opin Cell Biol 15:509–14PubMedGoogle Scholar
  48. 48.
    Li G, Satyamoorthy K, Herlyn M (2001) N-cadherin-mediated inter-cellular interactions promote survival and migration of melanoma cells. Cancer Res 61:3819–3825PubMedGoogle Scholar
  49. 49.
    Tran NL, Adams DG, Vaillancourt RR, Heimark RL (2002) Signal transduction from N-cadherin increases Bcl-2. Regulation of the phosphatidylinositol 3-kinase/Akt pathway by homophilic adhesion and actin cytoskeletal organization. J Biol Chem 277:32905–32914PubMedGoogle Scholar
  50. 50.
    Wheelock MJ, Johnson KR (2003) Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol 19:207–235PubMedGoogle Scholar
  51. 51.
    Darai E, Bringuier AF, Walker-Combrouze F, Feldmann G, Madelenat P, Scoaze JY (1998) Soluble adhesion molecules in serum and cyst fluid from patients with cystic tumors of the ovary. Hu Reprod 13:2831–2835Google Scholar
  52. 52.
    Silvertsen S, Berner A, Michael CW, Bedrossian C, Davidson B (2006) Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions. Acta Cytol 50:603–607Google Scholar
  53. 53.
    Roveri Marques F, Fonsechi-Carvasan GA, Andrade LAL, Luiz FB (2004) Immunohistochemical patterns for αand β catenin, E and N cadherin expression in ovarian epithelial tumors. Gyn Onc 94:16–24Google Scholar
  54. 54.
    Marques RF, Fonsechi-Carvasan GA, De Angelo Andrade LA, Bottcher-Luiz F (2004) Immunohistochemical patterns for alpha- and beta-catenin, E- and N-cadherin expression in ovarian epithelial tumors. Gynecol Oncol 94:16–24PubMedGoogle Scholar
  55. 55.
    Sarrio D, Moreno-Bueno G, Sanchez-Estevez C, Banon-Rodriguez I, Hernandez-Cortes G, Hardisson D, Palacios J (2006) Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. Hum Pathol 37:1042–1049PubMedGoogle Scholar
  56. 56.
    Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Lopes CS (2004) Prognostic value of E cadherin immunoexpression in patients with primary ovarian carcinomas. Ann Oncol 15(10):1535–1542PubMedGoogle Scholar
  57. 57.
    Maines-Bandiera SL, Auersperg N (1997) Increased E-cadherin expression in ovarian surface epithelium: an early step in metaplasia and dysplasia? Int J Gynecol Path 16:250–255CrossRefGoogle Scholar
  58. 58.
    Imai T, Horiuchi A, Shiozawa T, Osada R, Kikuchi N, Ohira S, Oka K, Konishi I (2004) Elevated expression of E-cadherin and alpha-, beta-, and gamma-catenins in metastatic lesions compared with primary epithelial ovarian carcinomas. Hum Pathol 35(12):1469–1467PubMedGoogle Scholar
  59. 59.
    Davies BR, Worsley SD, Ponder BA (1998) Expression of E cadherin, α-catenin and β-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopath 32:69–80Google Scholar
  60. 60.
    Qian X, Karpova T, Sheppard AM, McNally J, Lowy DR (2004) E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J 23:1739–1748PubMedGoogle Scholar
  61. 61.
    ho EY, Choi Y, Chae SW, Sohn JH, Ahn GH (2006) Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathol Int 56:62–70Google Scholar
  62. 62.
    Voutilainen KA, Anttila MA, Sillanpaa SM, Ropponen KM, Saarikoski SV, Juhola MT, Kosma VM (2006) Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer. J Clin Pathol 59:460–467PubMedGoogle Scholar
  63. 63.
    Veatch AL, Carson LF, Ramakrishnan S (1994) Differential expression of the cell-cell adhesion molecule E cadherin in ascites and solid human ovarian tumor cells. Int J Can 58:393–399Google Scholar
  64. 64.
    Bryant DM, Stow JL (2004) The ins and outs of E-cadherin trafficking. Trends Cell Biol 14:427–434PubMedGoogle Scholar
  65. 65.
    D’Souza-Schorey C (2005) Disassembling adherens junctions: breaking up is hard to do. Trends Cell Biol 15:19–26Google Scholar
  66. 66.
    Peinado H, Olmeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7:415–428PubMedGoogle Scholar
  67. 67.
    Wu R, Zhai Y, Fearon ER, Cho KR (2001) Diverse mechanisms of beta-catenin deregulation in ovarian endometroid carcinomas. Cancer Res 61(22):8247–8255Google Scholar
  68. 68.
    Oliva E, Sarrio D, Brachtel EF, Sanchez-Estevez C, Soslow RA, Moreno-Bueno G, Palacios J (2006) High frequency of beta-catenin mutations in borderline endometrioid tumours of the ovary. J Pathol 208:708–713PubMedGoogle Scholar
  69. 69.
    Rathi A, Virmani AK, Schorge JO, Elias KJ, Maruyama R, Minna JD, Mok SC, Girard L, Fishman DA, Gazdar AF (2002) Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res 8:3324–3331PubMedGoogle Scholar
  70. 70.
    Makarla PB, Saboorian MH, Ashfaq R, Toyooka KO, Toyooka S, Minna JD, Gazdar AF, Schorge JO (2005) Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 11:5365–5369PubMedGoogle Scholar
  71. 71.
    Yuecheng Y, Hongmei L, Xiaoyan X (2006) Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin Exp Metastasis 23:65–74PubMedGoogle Scholar
  72. 72.
    Kurrey NK, Amit K, Bapat SA (2005) Snail and Slug are major determinants of ovarian cancer invasiveness at the transcription level. Gynecol Oncol 97:155–165PubMedGoogle Scholar
  73. 73.
    Elloul S, Elstrand MB, Nesland JM, Trope CG, Kvalheim G, Goldberg I, Reich R, Davidson B (2005) Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 103:1631–1643PubMedGoogle Scholar
  74. 74.
    Elloul S, Silins I, Trope CG, Benshushan A, Davidson B, Reich R (2006) Expression of E-cadherin transcriptional regulators in ovarian carcinoma. Virchows Arch 449:520–528PubMedGoogle Scholar
  75. 75.
    Terauchi M, Kajiyama H, Yamashita M, Kato M, Tsukamoto H, Umezu T, Hosono S, Yamamoto E, Shibata K, Ino K, Nawa A, Nagasaka T, Kikkawa F (2007) Possible involvement of TWIST in enhanced peritoneal metastasis of epithelial ovarian carcinoma. Clin Exp Metastasis. May 9; [Epub ahead of print]Google Scholar
  76. 76.
    Hosono S, Kajiyama H, Terauchi M, Shibata K, Ino K, Nawa A, Kikkawa F (2007) Expression of twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients. Br J Cancer 96:314–320PubMedGoogle Scholar
  77. 77.
    Sundfeldt K, Ivarsson K, Rask K et al (2001) Higher levels of soluble E-cadherin in cyst fluid from malignant ovarian tumors than in benign cysts. Anticancer Res 21:65–70PubMedGoogle Scholar
  78. 78.
    Wheelock MJ, Buck CA, Bechtol KM, Damsky CH (1983) Soluble 80-kd fragment of cell-CAM120/80 disrupts cell–cell adhesion. J Cell Biochem 34:187–202Google Scholar
  79. 79.
    Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ (1997) Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 139:1861–1872PubMedGoogle Scholar
  80. 80.
    Noe V, Fingleton B, Jacobs K et al (2001) Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114:111–118PubMedGoogle Scholar
  81. 81.
    Maretzky T, Reiss K, Ludwig A et al (2005) ADAM10 mediated E-cadherin shedding and regulates epithelial cell–cell adhesion, migration and b-catenin translocation. Proc Natl Acad Sci USA 102:9182–9187PubMedGoogle Scholar
  82. 82.
    Symowicz J, Adley BP, Gleason KJ, Johnson JJ, Ghosh S, Fishman DA, Hudson LG, Stack MS (2007) Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent e-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res 67:2030–2039PubMedGoogle Scholar
  83. 83.
    Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED (2006) Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 66:11271–11278PubMedGoogle Scholar
  84. 84.
    Pon YL, Auersperg N, Wong AS (2005) Gonadotropins regulate N-cadherin-mediated human ovarian surface epithelial cell survival at both post-translational and transcriptional levels through a cyclic AMP/protein kinase A pathway. J Biol Chem 280:15438–15448PubMedGoogle Scholar
  85. 85.
    Burleson KM, Casey RC, Skubitz KM, Pambuccian SE, Oegema TR, Skubitz AP (2004) Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gyn Oncol 93:170–181Google Scholar
  86. 86.
    Burleson KM, Boente MP, Pambuccian SE, Skubitz AP (2006) Disaggregation and invasion of ovarian carcinoma ascites spheroids. J Transl Med 4:6PubMedGoogle Scholar
  87. 87.
    Wu C, Cipollone J, Maines-Bandiera S, Tan C, Karsan A, Auersperg N, Roskelley CD (2007) The morphogenic function of E-cadherin-mediated adherens junctions in epithelial ovarian carcinoma formation and progression. Differentiation. Jul 2; [Epub ahead of print]Google Scholar
  88. 88.
    Reddy P, Liu L, Ren C, Lindgren P, Boman K, Shen Y, Lundin E, Ottander U, Rytinki M, Liu K (2005) Formation of E-cadherin mediated cell–cell adhesion activates AKT and MAPK via PI3kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells. Mol Endocrinol 19:2564–2578PubMedGoogle Scholar
  89. 89.
    Shen X, Kramer RH (2004) Adhesion-mediated squamous cell carcinoma survival through ligand-independent activation of epidermal growth factor receptor. Am J Pathol 165:1315–1329PubMedGoogle Scholar
  90. 90.
    Lin Rz, Chou LF, Chien CC, Chang HY (2006) Dynamic analysis of hepatoma spheroid formation: roles of E-cadherin and beta1-integrin. Cell Tissue Res 324:411–422PubMedGoogle Scholar
  91. 91.
    Kang HG, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, Ng T, Reynolds CP, Triche TJ, Sorensen PH (2007) E-cadherin cell–cell adhesion in weing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res 67:3094–3105PubMedGoogle Scholar
  92. 92.
    Shield K, Riley C, Quinn MA, Rice GE, Ackland ML, Ahmed N (2007) alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog 6:11PubMedGoogle Scholar
  93. 93.
    Sutherland RM (1988) Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 240:177–184PubMedGoogle Scholar
  94. 94.
    Green SK, Francia G, Isidoro C, Kerbel RS (2004) Anti-adhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. Mol Cancer Ther 3:149–159PubMedGoogle Scholar
  95. 95.
    Desoize B, Jardillier J (2000) Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol 36:193–207PubMedGoogle Scholar
  96. 96.
    Bates RC, Edwards NS, Yates JD (2000) Spheroids and cell survival. Crit Rev Oncol Hematol 36:61–74PubMedGoogle Scholar
  97. 97.
    Minchinton AI, Tannock IF (2006) Drug penetration in solid tumors. Nat Rev Cancer 6:583–92PubMedGoogle Scholar
  98. 98.
    Frankel A, Rosen K, Filmus J, Kerbel RS (2001) Induction of anoikis and suppression of human ovarian tumor growth in vivo by down-regulation of Bcl-X(L). Cancer Res 61:4837–4841PubMedGoogle Scholar
  99. 99.
    Ning Y, Buranda T, Hudson LG (2006) Activated epidermal growth factor receptor induces integrin alpha2 internalization via caveolae/raft-dependent endocytic pathway. J Biol Chem 282:6380–6387PubMedGoogle Scholar
  100. 100.
    Zeineldin R, Rosenberg M, Ortega D, Buhr C, Chavez MG, Stack MS, Kusewitt DF, Hudson LG (2006) Mesenchymal transformation in epithelial ovarian tumor cells expressing epidermal growth factor receptor variant III. Mol Carcinog 45:851–860PubMedGoogle Scholar
  101. 101.
    Ning Y, Zeineldin R, Liu Y, Rosenberg M, Stack MS, Ludson LG (2005) down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation. Cancer Res 65:9280–9286PubMedGoogle Scholar
  102. 102.
    Do TV, Symowicz JC, Berman DM, Liotta LA, Petricoin EF, Stack MS, Fishman DA (2007) Lysophosphatidic acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells. Mol Cancer Res 5:121–131PubMedGoogle Scholar
  103. 103.
    Cowden-Dahl KD, Zeineldin R, Hudson LG (2007) PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian cancer cells. Mol Cancer Res 5:413–421PubMedGoogle Scholar
  104. 104.
    Fishman DA, Liu Y, Ellerbroek SM, Stack MS (2001) Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res 61:3194–3199PubMedGoogle Scholar
  105. 105.
    Ellerbroek SM, Hudson LG, Stack MS (1998) Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion. Int J Cancer 78:331–337PubMedGoogle Scholar
  106. 106.
    Ellerbroek SM, Halbleib JM, Benavidez M, Warmka JK, Wattenberg EV, Stack MS, Hudson LG (2001) Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res 61:1855–1861PubMedGoogle Scholar
  107. 107.
    Fishman DA, Bafetti LM, Banionis S, Kearns AS, Chilukuri K, Stack MS (1997) Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer 80:1457–1463PubMedGoogle Scholar
  108. 108.
    Young TN, Rodriguez GC, Rindhart AR, Bast RC Jr, Pizzo SV, Stack MS (1996) Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol 62:89–99PubMedGoogle Scholar
  109. 109.
    Choi JH, Choi KC, Auersperg N, Leung PC (2004) Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells. J Clin Endocrinol metab 89:5508–16PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Laurie G. Hudson
    • 1
  • Reema Zeineldin
    • 1
  • M. Sharon Stack
    • 2
  1. 1.Department of Pharmaceutical Sciences, College of PharmacyUniversity of New MexicoAlbuquerqueUSA
  2. 2.Department of Pathology and Anatomical Sciences, School of MedicineUniversity of MissouriColumbiaUSA

Personalised recommendations